Developing A 1st Of Its Kind Point-of Care Functional Hemostasis Diagnostic Platform
Easily adaptable with broad clinical utility
Only hemostasis testing platform that simulates the biological microenvironment of clot formation as it occurs in-vivo
Combining hemodynamic flow and discrete lot activation to facilitate real-time evaluation of blood clot physiology and clotting abnormalities.
Dynamic, multiplex evaluation of flowing blood, evaluating platelet and fibrin function
Fluorescent signals are translated into fluorescent intensity scores that represent platelet and fibrin accumulation.
FloBio is developing, in conjunction with clinician feedback, a user friendly, easy to interpret and unique decision support tool.
We are developing a point-of-care IVD product that includes a table top analyzer, disposable cartridge and proprietary software.
Why it matters:
“As healthcare systems continue to focus on cost-effective, quality patient care, particularly in emergency, trauma, and critical care settings, FloBio’s innovative approach to hemostasis testing will have the potential to help clinicians optimize clinical decision making, while positively impacting hospitals’ blood product stewardship and DOAC/blood thinner safe use goals.”
Dr. Alan Wright, VP of Medical Affairs bioMérieux
Growing Safety Concerns With Blood Thinners
Blood thinners are the #1 cause of drug related emergency visits, costing US hospitals more than $2.5B annually. Newer drugs, direct oral anticoagulants (DOACs), are growing and taking a lead in the blood thinner market, increasing the demand for a rapid, accessible test that can help clinicians understand the need for reversal to safely manage these complex patients.
Uncontrolled Bleeding #1 Cause Of Preventable Death
Abnormal blood clotting represents a major risk factor for emergency room patients and can lead to care complications. This is especially problematic in emergency trauma care, where surgical/procedural and treatment decisions must be made in the critical 15-20 minute triage window to avoid severe bleeding complications, which increase healthcare costs, poor health outcomes, morbidity and death.
ADDITIONAL SELECT PUBLICATIONS
- Zhu, S., B. A. Herbig, X. Yu, J. Chen, and S. L. Diamond. 2018. ‘Contact Pathway Function During Human Whole Blood Clotting on Procoagulant Surfaces’, Front Med (Lausanne), 5: 209.
- Li, R., K. A. Panckeri, P. F. Fogarty, A. Cuker, and S. L. Diamond. 2017. ‘Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation’, Haemophilia, 23: 759-68.
- Kaza, E. A., M. C. Egalka, H. Zhou, J. Chen, D. Evans, J. Prats, R. Li, S. L. Diamond, J. A. Vincent, E. A. Bacha, and T. G. Diacovo. 2017. ‘P2Y12 Receptor Function and Response to Cangrelor in Neonates With Cyanotic Congenital Heart Disease’, JACC Basic Transl Sci, 2: 465-76.
- Li, R., T. Grosser, and S. L. Diamond. 2017. ‘Microfluidic whole blood testing of platelet response to pharmacological agents’, Platelets, 28: 457-62.
- Li, R., H. Elmongy, C. Sims, and S. L. Diamond. 2016. ‘Ex vivo recapitulation of trauma-induced coagulopathy and preliminary assessment of trauma patient platelet function under flow using microfluidic technology’, J Trauma Acute Care Surg, 80: 440-9.
- Li, R., K. A. Panckeri, P. F. Fogarty, and S. L. Diamond. 2015. ‘Recombinant factor VIIa enhances platelet deposition from flowing haemophilic blood but requires the contact pathway to promote fibrin deposition’, Haemophilia, 21: 266-74.
- Zhu, S., B. A. Herbig, R. Li, T. V. Colace, R. W. Muthard, K. B. Neeves, and S. L. Diamond. 2015. ‘In microfluidico: Recreating in vivo hemodynamics using miniaturized devices’, Biorheology, 52: 303-18.
- Colace, T. V., R. W. Muthard, and S. L. Diamond. 2012. ‘Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin’, Arterioscler Thromb Vasc Biol, 32: 1466-76.